Gold-Containing Nanoplatforms for Preclinical Spinal Cord Injury: A Scoping Review and Evidence Map
Tissue Engineering Part B: Reviews · 18.11.2026
DOI: 10.1177/19373368261506877 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tissue Engineering Part B: Reviews, online erschienen am 18.11.2026. Verfasst von Ding Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, China. Die Arbeit nennt 76 Literaturangaben. Gefördert von: Jilin Provincial Science and Technology Development Program Project.
Abstract (Originalsprache)
Gold-containing nanoplatforms are increasingly investigated for spinal cord injury (SCI), but their roles within heterogeneous therapeutic systems remain difficult to compare. We conducted a scoping review and evidence map to characterize preclinical SCI studies by platform function, the role of the gold-containing component, and the breadth of experimental validation. Following PRISMA-ScR and JBI guidance, PubMed, Scopus, Web of Science, and Embase were searched from inception to May 26, 2026. Twenty-seven eligible in vivo studies were charted using eight mutually exclusive primary platform categories and nonexclusive biointerface and outcome domains. The most frequent categories were cargo and transcriptional modulation ( n = 8), conductive and stimulation-associated interfaces ( n = 5), and scaffold and cell support ( n = 4). Four recurrent repair problems emerged: local delivery and pathway modulation, lesion bridging and cell retention, bioelectrical support, and secondary-injury microenvironment regulation. Most studies used rats (21/27), thoracic injury models (23/27), and acute intervention contexts (24/27). Motor function and tissue preservation were each evaluated in 24 studies, while sensory, bladder, and respiratory outcomes were less common. Relevant gold-free comparisons were included in 21 studies, including 17 in vivo . Biodistribution, degradation, and clearance or excretion were each assessed in four studies. SYRCLE appraisal identified widespread unclear reporting of key allocation and blinding procedures. These findings suggest that gold is best evaluated as a platform-dependent biointerface rather than a uniform therapeutic agent. More component-resolved controls, longer-term material-fate studies, standardized outcomes, and rigorous reporting are needed to advance reproducible preclinical evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, China.
- Department of Oral Implantology, School and Hospital of Stomatology, Jilin University, Changchun, China.
- Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, China.
ORCID-Profile: Ding Zhang
Förderung
- Jilin Provincial Science and Technology Development Program Project
Zitieren
APA
Zhang, D., Liu, J., Yi, X., & Yin, F. (2026). Gold-Containing Nanoplatforms for Preclinical Spinal Cord Injury: A Scoping Review and Evidence Map. Tissue Engineering Part B: Reviews. https://doi.org/10.1177/19373368261506877
Vancouver
Zhang D, Liu J, Yi X, Yin F. Gold-Containing Nanoplatforms for Preclinical Spinal Cord Injury: A Scoping Review and Evidence Map. Tissue Engineering Part B: Reviews. 2026. doi:10.1177/19373368261506877
BibTeX
@article{Zhang2026,
author = {Zhang, Ding and Liu, Jia and Yi, Xingcheng and Yin, Fei},
title = {Gold-Containing Nanoplatforms for Preclinical Spinal Cord Injury: A Scoping Review and Evidence Map},
journal = {Tissue Engineering Part B: Reviews},
year = {2026},
doi = {10.1177/19373368261506877}
}
EUVIMED